Psoriatic arthritis: treatment strategies using biologic agents

被引：15

作者：

D'Angelo, S. ^{[1
,2
]}

Palazzi, C. ^{[1
,2
]}

Olivieri, I. ^{[1
,2
]}

机构：

[1] San Carlo Hosp Potenza, Rheumatol Dept Lucania, I-85100 Potenza, Italy

[2] Madonna Grazie Hosp Matera, Potenza, Italy

来源：

REUMATISMO | 2012年 / 64卷 / 02期

关键词：

Psoriatic disease; psoriatic arthritis; therapy; biologic drugs; anti-TNF alpha agents;

D O I：

10.4081/reumatismo.2012.113

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The traditional management of psoriatic arthritis (PsA) includes NSAIDs, corticosteroids and DMARDs. Advancement in the knowledge of the immunopathogenesis of PsA has been associated with the development of biologic agents which have revolutionized the management of the disease. Among biologics drugs, there are the 4 currently available anti-TNF alpha blocking agents (etanercept, infliximab, adalimumab and golimumab) which are more effective than traditional DMARDs on symptoms/signs of inflammation, quality of life, function, and in inhibiting the progression of the structural joint damage. Despite of the high cost, TNF inhibitors are costeffective on both the musculoskeletal and skin manifestations of psoriatic disease.

引用

页码：113 / 121

页数：9

共 53 条

[1] The diagnosis and treatment of early psoriatic arthritis [J].

Anandarajah, Allen P. ;

Ritchlin, Christopher T. .

NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (11) :634-641

[2] Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J].

Antoni, C ;

Krueger, GG ;

de Vlam, K ;

Birbara, C ;

Beutler, A ;

Guzzo, C ;

Zhou, B ;

Dooley, LT ;

Kavanaugh, A .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1150-1157

[3] Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].

Antoni, CE ;

Kavanagh, A ;

Kirkham, B ;

Tutuncu, Z ;

Burmester, GR ;

Schneider, U ;

Furst, DE ;

Molitor, J ;

Keystone, E ;

Gladman, D ;

Manger, B ;

Wassenberg, S ;

Weier, R ;

Wallace, DJ ;

Weisman, MH ;

Kalden, JR ;

Smolen, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236

[4]

Antoni CE, 2008, J RHEUMATOL, V35, P869

[5] A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis [J].

Ash, Zoe ;

Gaujoux-Viala, Cecile ;

Gossec, Laure ;

Hensor, Elizabeth M. A. ;

FitzGerald, Oliver ;

Winthrop, Kevin ;

van der Heijde, Desiree ;

Emery, Paul ;

Smolen, Josef S. ;

Marzo-Ortega, Helena .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (03) :319-326

[6] Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis [J].

Bansback, N. J. ;

Ara, R. ;

Barkham, N. ;

Brennan, A. ;

Fraser, A. D. ;

Conway, P. ;

Reynolds, A. ;

Emery, P. .

RHEUMATOLOGY, 2006, 45 (08) :1029-1038

[7] Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis:: an observational study over a 5-year period [J].

Conti, Fabrizio ;

Ceccarelli, Fulvia ;

Marocchi, Elisa ;

Magrini, Leonardo ;

Spinelli, Francesca Romana ;

Spadaro, Antonio ;

Scrivo, Rossana ;

Valesini, Guido .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (10) :1393-1397

[8]

Cummins E, 2011, EUR J HLTH EC

[9]

D'Angelo S, 2011, CLIN EXP RHEUMATOL, V29, P865

[10] EVIDENCE-BASED MEDICINE - WHY ALL THE FUSS [J].

DAVIDOFF, F ;

CASE, K ;

FRIED, PW .

ANNALS OF INTERNAL MEDICINE, 1995, 122 (09) :727-727

← 1 2 3 4 5 6 →